Nootropics Index - Save on smarter supplements
Nootropics>Botanical & herbal supplements>Rhodiola Rosea
Botanical & herbal supplements

Rhodiola Rosea

Rhodiola rosea L. root and rhizome

Rhodiola rosea is a root-and-rhizome botanical, not a generic adaptogen category. The European Medicines Agency has an extract-specific traditional-use range; other studies use different preparations. Compare the exact extract, standardization, daily labeled amount and credible evidence rather than assuming marker percentages are interchangeable doses.

Mental EnergyFatigue ResistanceStress ResiliencePhysical PerformanceStandardized ExtractTraditional UseClinical Research
Updated October 2026/7 min read/11 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

A botanical identity, not one interchangeable extract

3

Rhodiola rosea is a Crassulaceae species whose dried root and rhizome are used in powders and extracts. Human studies and the EMA monograph refer to specific preparations, so a result for SHR-5 or an ethanol dry extract should not be assumed for every product labelled rhodiola.

Evidence bottom line4
Stress-fatigue and exercise studies produce some positive signals, but results are heterogeneous, short-term, and preparation-specific. NCCIH says reliable evidence is still insufficient for any health-related purpose.

Match the species before comparing prices

3

Check the full species and root/rhizome preparation on each product label. Rhodiola crenulata is a different species; genus-only or mixed-species listings cannot be assumed equivalent to the R. rosea preparations reviewed here. Listed amounts and normalized prices are catalog data, not validated dosing evidence.

02

Names, aliases and forms

Scientific NameRhodiola rosea L.
Common Namesgolden root; rose root; Arctic root; rosenroot; king's crown
03

Potential effects and evidence map

Human evidence remains mixed and product-specific. Older fatigue reviews and EMA found contradictory or methodologically weak trials, while newer exercise reviews and small trials report possible performance signals. A 2026 adaptogen review included only five Rhodiola RCTs and still noted short durations, small samples, and substantial heterogeneity. These findings support grade C rather than a dependable stress, cognition, mood, or performance claim.

Effect domainMagnitudeGrade
Stress resilience5
CumulativeConfidence: Medium

Small, extract-specific trials show a possible signal for fatigue and strain in stressed populations, but systematic and regulatory reviews find the evidence inconsistent.

Note Do not generalize traditional-use status or one branded extract to a reliable stress benefit.

2/5
C
Mental energy / wakefulness6
CumulativeConfidence: Low

Some small repeated-use trials report less mental fatigue under stress, but validated everyday energy benefits are not established.

Note This is not evidence of stimulant-like wakefulness.

1/5
C
Focus / attention3
Acute + cumulativeConfidence: Low

Attention findings appear mainly in small fatigue-challenge studies and are not dependable evidence for routine focus enhancement.

Note EMA judged several older mental-performance tests insufficient for clinically relevant conclusions.

1/5
C
Physical energy / endurance8
Acute + cumulativeConfidence: Medium

A 2025 meta-analysis reported small endurance signals, but products, doses, training protocols, and study quality varied substantially.

Note Regard this as a research signal, not a dependable performance outcome for every extract.

2/5
C
04

Typical dosages and timing

Typical
144-400 mg/day
Not a recommendation
Lower bound
144 mg/day
Profile value
Upper bound
400 mg/day
Profile value
extract ratio2DER 1.5-5:1

The 2024 EU monograph covers a dry extract made with 67-70% ethanol. DER is the drug-to-extract ratio: the amount of dried plant material used to make one part of extract. This specification does not describe every supplement.

extract7SHR-5

A specific standardized extract used in several older trials; its results should not be generalized to unrelated powders or extracts.

specified extract2144-400 mg/day

The range shown in the profile card applies to the 67-70% ethanol dry extract specified in the European Medicines Agency monograph. It is not a universal target for raw root powder, every standardized extract or an individual supplementation plan. Compare products by the exact extract and labeled daily amount.

study dose7576 mg/day

The 28-day Olsson trial used SHR-5. It provides study context, not a universal target dose.

05

Timing & effect horizon

Effect horizonAcute + cumulative
AcuteCumulative
Constituent blood peak3Acute
2 hours
Plasma detectability3Acute
8 hours
Stress-fatigue RCT7Cumulative
28 days
Safety data window4Cumulative
12 weeks
How to read the timing cards3

The 2-hour peak and 8-hour detectability figures describe rhodioloside and rosavin concentrations after one 288 mg SHR-5 dose; they are not proven effect onset or duration. The 28-day and 12-week cards are study and safety windows, not recommended cycle lengths.

06

Safety, side effects and risk profile

Why the overall tier is minimal3
Reported effects at typical short-term oral use are mainly mild and reversible, and EMA concludes that specified traditional products are not harmful when used under the monograph conditions. Product quality and special-population gaps remain separate cautions.
Pregnancy and breastfeeding2
Safety has not been established. EMA does not recommend use during pregnancy or breastfeeding because adequate data are absent.
Headache / dizziness4
Confidence: High

Headache and dizziness are documented short-term tolerability issues; frequency is not well quantified.

Note Usually a mild, reversible concern at typical oral use.

1/5
C
GI discomfort2
Confidence: High

EMA lists nausea, abdominal pain, and diarrhea with unknown frequency.

Note Ordinary tolerability issue rather than a profile-level moderate hazard.

1/5
C
Overstimulation / insomnia4
Confidence: Medium

NCCIH lists insomnia, dry mouth, or excess saliva; activating effects are possible but not well quantified.

Note The frequency and dose relationship of activating effects are not well quantified.

1/5
C
Pregnancy / lactation caution2
Confidence: High

Pregnancy and breastfeeding safety have not been established; EMA does not recommend use because data are insufficient.

Note This is a special-population data gap, not evidence of a general healthy-adult hazard.

Unscored
E
mild effects4headache / GI / insomnia

NCCIH lists dizziness, headache, insomnia, dry mouth, or excess saliva. EMA additionally lists nausea, abdominal pain, diarrhea, rash, and itching; frequencies are not established.

07

Interactions and cautions

narrow, mixed signal3

NCCIH reports a Rhodiola-losartan interaction concern. EMA reviewed a small human enzyme study that found altered losartan metabolism with unclear clinical relevance, while its monograph states that no clinically relevant interactions have been observed. These findings do not establish the safety of every drug combination.

08

Legal and regulatory status

European Union, 20262

EMA's March 2024 monograph covers a specified dry extract as a traditional herbal medicinal product for stress symptoms such as fatigue and exhaustion. The status is based on long-standing use and is not a finding of well-established clinical efficacy.

United States, 202611

In the United States, oral rhodiola products are generally marketed as dietary supplements. FDA does not approve dietary supplements before sale, and disease claims can place a product under drug requirements.

09

Practical buying and quality notes

  • Rosavins and salidroside are useful for identity and batch comparison. Percentages differ across preparations and do not by themselves prove clinical equivalence or effect strength.10
  • Normalize price by the labelled daily dose and extract specification. Check R. rosea species, root/rhizome, extract ratio and solvent, rosavins/salidroside results, batch certificate of analysis (COA) date, and independent identity and heavy-metal testing. In ten U.S. products purchased in 2024, marker concentrations varied widely and several missed label targets; that small sample does not estimate the whole market.10
10

FAQ

Is Rhodiola rosea a reliable nootropic?

3

No reliable broad nootropic effect is established. Small studies suggest possible mental-fatigue or attention effects under stress, but they do not show dependable everyday focus or memory enhancement.

What Rhodiola rosea dosage has official monograph support?

2

The European Medicines Agency range shown in the profile card applies to one specific 67-70% ethanol dry extract. A key 28-day fatigue trial used 576 mg/day of SHR-5 extract, illustrating why a percentage marker or milligram amount alone does not establish equivalence across products.

How long has Rhodiola rosea been studied, and is cycling required?

4

Human research includes single-dose experiments and repeated use up to 12 weeks, but study exposure is not proven effect duration or a recommended cycle. Evidence does not establish that cycling is required, and longer-term safety remains uncertain.

Does minimal risk mean risk-free?

4

No. Minimal describes typical short-term oral use in generally healthy adults. Mild side effects, pregnancy and breastfeeding data gaps, the narrow losartan concern, and product-quality variation still matter.

11

References

  1. Royal Botanic Gardens, Kew. Plants of the World Online: Rhodiola rosea L.
  2. European Medicines Agency. European Union herbal monograph on Rhodiola rosea L., rhizoma et radix. Final Revision 1. EMA/HMPC/24177/2023. 20 March 2024.
  3. European Medicines Agency. Assessment report on Rhodiola rosea L., rhizoma et radix. Final Revision 1. EMA/HMPC/24186/2023. 20 March 2024.
  4. National Center for Complementary and Integrative Health. Rhodiola: Usefulness and Safety. Updated April 2025.
  5. Ishaque S, Shamseer L, Bukutu C, Vohra S. Rhodiola rosea for physical and mental fatigue: a systematic review. BMC Complement Altern Med. 2012;12:70.
  6. Darbinyan V, Kteyan A, Panossian A, et al. Rhodiola rosea in stress induced fatigue: a double blind cross-over study of SHR-5 in physicians during night duty. Phytomedicine. 2000;7(5):365-371.
  7. Olsson EM, von Scheele B, Panossian AG. A randomised, double-blind, placebo-controlled study of SHR-5 in subjects with stress-related fatigue. Planta Med. 2009;75(2):105-112.
  8. Wang X, Yang X, Gao Z, Zeng J, Liu Y. The effect of Rhodiola rosea supplementation on endurance performance and related biomarkers: a systematic review and meta-analysis. Front Nutr. 2025;12:1645346.
  9. Luszczak J, Kocki J. Clinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea: a systematic review with molecular interpretation of psychometric outcomes. Ann Agric Environ Med. 2026;33(1):3-11.
  10. Porwollik S, Jafari M. The quality and safety of Rhodiola rosea supplements on the U.S. market: an analysis of biomarkers, heavy metals, and pesticide residues. PLoS One. 2026;21(1):e0341070.
  11. U.S. Food and Drug Administration. Dietary Supplements.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.